Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Japan. This a clinical trial to study the efficacy and safety of three times a day BIAsp-70 compared to two times a day BIAsp-30 in subjects with type 2 diabetes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin Aspart

Criteria

Inclusion Criteria:

• Subjects with type 2 diabetes

• Current treatment using intermediate-acting, long-acting insulin (including long-acting insulin analogue) or pre-mixed human insulin for at least 24 weeks

• HbA1c at least 7.5% and below 10.0%

Exclusion Criteria:

• Proliferative retinopathy or maculopathy requiring acute treatment

• Impaired hepatic and/or renal function

• Cardiac diseases

• Uncontrolled hypertension

• Known hypoglycemia unawareness or recurrent major hypoglycemia